Stocks and Investing
Stocks and Investing
Thu, March 10, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, March 9, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Jacob Johnson Maintained (CDMO) at Buy with Decreased Target to $28 on, Mar 9th, 2022
Jacob Johnson of Stephens & Co., Maintained "Avid Bioservices, Inc." (CDMO) at Buy with Decreased Target from $31 to $28 on, Mar 9th, 2022.
Jacob has made no other calls on CDMO in the last 4 months.
There are 3 other peers that have a rating on CDMO. Out of the 3 peers that are also analyzing CDMO, 1 agrees with Jacob's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Paul Knight of "Keybanc" Downgraded from Buy to Hold on, Wednesday, December 8th, 2021
These are the ratings of the 2 analyists that currently disagree with Jacob
- Matt Hewitt of "Craig-Hallum" Maintained at Strong Buy with Increased Target to $35 on, Wednesday, December 8th, 2021
- Sean Dodge of "RBC Capital" Maintained at Buy with Increased Target to $32 on, Wednesday, December 8th, 2021
Contributing Sources